Michael Darley, MD
Rheumatology · Provo, UTNPI 1538458146
Payments from drug & device makers
Across 860 payments — averaging $14.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AbbVie$2K
- Pfizer$1K
- Johnson & Johnson$979
- Novartis$938
- UCB, Inc.$783
- plus $3K from 33 others
What the payments were for
- Speaking & faculty fees$1,25010%
- Food & beverage$11,08587%
- Education$4333%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 259 | $3,114 |
| AbbVie | 82 | $2,413 |
| Pfizer | 213 | $1,135 |
| Johnson & Johnson | 40 | $979 |
| Novartis | 57 | $938 |
| UCB, Inc. | 32 | $783 |
| Lilly USA, LLC | 26 | $556 |
| AstraZeneca(2 entities) | 21 | $537 |
| GSK | 20 | $321 |
| Boehringer Ingelheim | 8 | $175 |
| Genentech USA, Inc. | 9 | $160 |
| ANI Pharmaceuticals, Inc. | 9 | $159 |
| Organon | 10 | $156 |
| E.r. Squibb & Sons, L.L.C. | 8 | $156 |
| Sanofi | 7 | $152 |
| Bristol Myers Squibb | 9 | $130 |
| Sobi, Inc | 6 | $92 |
| Fresenius Kabi USA, LLC | 1 | $82 |
| Sandoz | 4 | $77 |
| Regeneron Healthcare Solutions, Inc. | 5 | $72 |
| Mallinckrodt Hospital Products Inc. | 4 | $69 |
| Gilead | 4 | $67 |
| Radius Health, Inc. | 3 | $50 |
| Merck | 4 | $49 |
| Boston Scientific | 2 | $44 |
| Aurinia Pharma U.S., Inc. | 2 | $37 |
| Shorla Oncology Inc. | 1 | $34 |
| Amneal Pharmaceuticals LLC | 2 | $32 |
| Actelion Pharmaceuticals US, Inc. | 2 | $32 |
| IBSA Pharma Inc. | 1 | $23 |
| Biocryst US Sales Co., LLC | 1 | $22 |
| Mylan Institutional Inc. | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Vivus LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| CMP Pharma, Inc. | 1 | $14 |
| Kaleo, Inc. | 1 | $13 |
| Optinose US, Inc. | 1 | $13 |
| Antares Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,767 in reported general payments places this provider in the 70th percentile of 52 rheumatology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 51 | $409,404 |
| RinvoqUpadacitinib | 63 | $407,429 |
| Humira(Cf)Adalimumab | 26 | $184,972 |
| Humira(Cf) PenAdalimumab | 15 | $168,932 |
| Orencia ClickjectAbatacept | 22 | $128,551 |
| EnbrelEtanercept | 17 | $108,863 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 13 | $92,170 |
| Cosentyx Sensoready PenSecukinumab | 12 | $90,315 |
| OrenciaAbatacept | 13 | $83,042 |
| OlumiantBaricitinib | 13 | $33,319 |
| Hydroxychloroquine Sulfate | 285 | $19,373 |
| MethotrexateMethotrexate Sodium | 398 | $12,516 |
| Celecoxib | 187 | $9,884 |
| Leflunomide | 125 | $7,309 |
| Pilocarpine Hcl | 31 | $3,738 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $2,413 | $592,40189 claims |
| AmgenEnbrel | $3,114 | $108,86317 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $156 | $83,04213 claims |
| Lilly USA, LLCOlumiant | $556 | $33,31913 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil | $32 | $1,54611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 52 rheumatology providers in Utah.
Other rheumatology in Provo
- Wenshu YuProvo$17K
- James SteierProvo$2K
- Richard CallProvo$52
- Jessica WalshSlc$1.4M
- Catherine BakewellSalt Lake City$1.2M
- Brayden YellmanMurray$452K
- Grant CannonSalt Lake City$187K
- Shruti SanghviVineyard$63K
- Curry KoeningSalt Lake City$63K
- Carmen GotaSt. George$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.